Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03457857 · ClinicalTrials.gov registry record · NA
Evaluation of Two Regimens, With Healthy Male and Female Babies, Ages 3-6 Months Old, Using Various Assessments.
A NA study of Microbiome, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT03457857: Completed NA study of Microbiome, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
NCT03457857 is a NA study of Microbiome that has completed, run by Johnson & Johnson Consumer Inc. (J&JCI). The registered enrollment target is 38 participants, below the 140-participant average among 12 other Microbiome trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03457857, a NA study of Microbiome, has completed, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to assess the impact of two skincare regimens on the cutaneous microbiome and skin physiology of healthy male and female infants, ages 3-6 months using clinical, instrumental, D-Squame tape, microbiome and parental assessments over a five-week period.
Primary Outcome
Skin hydration as assessed by mean Corneometer measurements on the dorsal forearm. Group 2 with baby lotion will also be assessed by dry down of lotion at Baseline (Day 0)
Conditions Studied
Interventions
- OTHER Cleanser
- OTHER Cleanser and Lotion
Study Locations (1)
New Jersey
- Johnson & Johnson Consumer Experience Center - Skillman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-01-10 |
| Est. Completion | 2018-05-11 |
| Phase | NA |
What the finished NCT03457857 record still lists
NCT03457857 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 140-participant average among 12 other Microbiome trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Microbiome appearing as the primary indexed condition, and to 2 interventions - of which Cleanser is the first listed.
NCT03457857 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT03457857 about?
NCT03457857 is a clinical study titled "Evaluation of Two Regimens, With Healthy Male and Female Babies, Ages 3-6 Months Old, Using Various Assessments.". This study is to assess the impact of two skincare regimens on the cutaneous microbiome and skin physiology of healthy male and female infants, ages 3-6 months using clinical, instrumental, D-Squame tape, microbiome and parental assessments over a five-week period.
What is the current status of trial NCT03457857?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2018-01-10. Estimated completion is 2018-05-11.
What conditions does trial NCT03457857 study?
This clinical trial studies the following conditions: Microbiome.
What interventions are being tested in trial NCT03457857?
The interventions under investigation include: Cleanser (OTHER), Cleanser and Lotion (OTHER).
Who is sponsoring clinical trial NCT03457857?
This trial is sponsored by Johnson & Johnson Consumer Inc. (J&JCI), which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03457857 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Microbiome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03457857's enrollment target sits among peer trials
38 9th of 12 higher than 2 of 12 other Microbiome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Microbiome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Flourish: Exploring the Early Infant Gut Microbiome
RECRUITING · NA
-
Infant Restore: Efficacy of Microbiome Analysis and Education
ACTIVE NOT RECRUITING · NA
-
IGNITE Firefighters' Health
ACTIVE NOT RECRUITING · NA
-
Alcoholic Liver Disease and the Gut Microbiome
ACTIVE NOT RECRUITING · NA
-
Maternal & Offspring Microbiome Study
ACTIVE NOT RECRUITING · NA
-
Effect of Strawberry Consumption on the Microbiome
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI